Protection from harmful pathogens depends on activation of the immune system, which
relies on tight regulation of gene expression. Recently, the RNA modification N 6 …

Dendritic cells (DCs) play a central role in the regulation of the balance between CD8 T cell
immunity vs. tolerance to tumor antigens. Cross-priming, a process which DCs activate CD8 …

Since the discovery of MHC molecules, it has taken 40 years to arrive at a coherent picture
of how MHC class I and MHC class II molecules really work. This is a story of the proteases …

The tremendous clinical success of checkpoint blockers illustrates the potential of
reestablishing latent immunosurveillance for cancer therapy. Although largely neglected in …

In vitro-transcribed messenger RNA-based therapeutics represent a relatively novel and
highly efficient class of drugs. Several recently published studies emphasize the potential …

Dying cells have an important role in the initiation of CD8+ T cell-mediated immunity. The
cross-presentation of antigens derived from dying cells enables dendritic cells to present …

The molecular details of antigen processing and presentation by MHC class I and class II
molecules have been studied extensively for almost three decades. Although the basic …

Sixteen years ago, the Nomenclature Committee of the International Union of Pharmacology
approved a system for naming human seven-transmembrane (7TM) G protein-coupled …

Activating CD8+ T cells by antigen cross-presentation is remarkably effective at eliminating
tumours. Although this function is traditionally attributed to dendritic cells, tumour-associated …

Dendritic cell (DC)-mediated cross-presentation of exogenous antigens acquired in the
periphery is critical for the initiation of CD8+ T cell responses. Several DC subsets are …